Nonspecific anti-inflammatories like steroids might be entirely sidelined for mild-to-moderate chronic hand eczema now that three targeted topical agents are available.
AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...
According to newly published research, the exposure to nature provided by the Re-Connecting Nature forest microbe extract has ...
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from ...
The demand for ZORYVE cream, a phosphodiesterase-4 inhibitor formulated for plaque psoriasis and atopic dermatitis treatments ...
Parents of children with eczema are more likely to be short on sleep and to use medication to try to get more of it, a ...
This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to ...
Allergic diseases such as asthma, atopic dermatitis, and food allergies have been increasing in frequency over the last few ...
KKH and the National Skin Centre say there are more such patients, but no recent studies have been done. Read more at ...
The prevalence of eczema in Singapore has been largely stable in the past decade, affecting about one in five children and ...
Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback